PARIS, June 29 — Ipsen has signed a definitive agreement to acquire Kartos Therapeutics, a move that bolsters its late-stage hemato-oncology pipeline with a drug aimed at a stubborn problem in myelofibrosis treatment. The mechanics here are straightforward: Ipsen gets navtemadlin, an investigational MDM2 inhibitor designed to restore the tumor-suppressing function of p53. The target is patients with intermediate and high-risk TP53 wild-type myelofibrosis who have a suboptimal response to the current standard of care, ruxolitinib.
The catch is that ruxolitinib, while effective at improving splenomegaly and myelofibrosis-related symptoms, leaves a significant proportion of patients with a suboptimal response. Those patients often discontinue treatment.
On closer reading of the data, outcomes after stopping ruxolitinib are described as dismal, with a median overall survival of approximately one to two years. That is the gap Kartos’s drug is meant to fill. Navtemadlin is currently being evaluated in the global Phase III trial POIESIS, designed to enroll more than 600 patients across over 250 sites.
The trial is testing it as an add-on therapy to standard of care. Ipsen’s CEO David Loew framed the acquisition as strengthening the company’s late-stage oncology pipeline and reflecting a continued focus on bringing transformational treatments to cancer patients.
He expressed excitement about navtemadlin’s potential to define a new treatment paradigm, addressing what he called a critical care gap, with the possibility of a new therapeutic option as early as 2028. Follow the money: Ipsen, headquartered in Paris and listed on Euronext with an ADR on the US market, is buying a private US biotech based in Redwood City, California. The deal adds a late-stage asset to a pipeline that now has a shot at a defined patient population with clear unmet need.
The drug’s mechanism is worth noting. MDM2 inhibitors work by blocking the protein that disables p53, a critical tumor suppressor. In TP53 wild-type myelofibrosis, p53 is still functional but suppressed; navtemadlin aims to flip that switch back on.
The data so far suggest strong therapeutic potential for the add-on indication. What to watch next: enrollment and data from the POIESIS trial, and whether the 2028 timeline for a potential new option holds.
For now, Ipsen has placed a bet on a specific mechanism for a specific subset of myelofibrosis patients — those with the worst outlook after standard therapy fails. Consult your doctor for medical advice.
